Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
Everbridge xMatters to Host London Event on the Future of Incident Management February 23, 2026 Everbridge, Inc., the global leader in High Velocity Critical Event Management (CEM) and national public warning solutions, will host an exclusive customer event on March 17 at the Churchill War Rooms in London, bringing together IT, DevOps, and operational leaders to discuss the evolving demands of modern incident management and operational resilience. This press release [...]
This ski holiday high in the Swiss Alps has serious Wes Anderson credentials February 23, 2026 #The Jungfrau region of Switzerland’s Bernese Oberland is home to some of the Alps’ finest skiing and most historic runs. Other destinations offer fashion parades of vintage furs, nightclub ceilings dripping with Dom Perignon, and truffled pizzas at £100 a pie. That’s not what you’ll find here. This is the anti-Zermatt, where après ski is [...]
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
CBRE IM Backs IPUT Real Estate Dublin with Significant Equity Commitment February 23, 2026 - CBRE IM to increase investment in IPUT by €175m - Capital will kick-start a €500m IPUT Real Estate’s office investment programme - IPUT Real Estate is a market leader with a €2.7bn portfolio
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM February 23, 2026 Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy
Options Announces 15 Consecutive Years of SOC Compliance, Underlying Its Commitment to Delivering Secure Reliable Solutions February 23, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institutions, today announced that it has achieved SOC compliance for the 15th consecutive year, adhering to Type 2 SOC 1 & ISAE 3402, Type 2 SOC 2, and Type 2 SOC 3 standards. Danny Moore, President and CEO at Options said, “From the [...]
The Monarchy will survive Andrew’s arrest February 23, 2026 If Andrew is found guilty of misconduct, or if he is proven somehow to be a sexual predator of the worst kind, the law will take its course, as the King has indicated. Embarrassing? Undoubtedly. But not terminal, says Eliot Wilson It was an historic event. At 8am last Thursday, his 66th birthday, Andrew Mountbatten-Windsor [...]
Motive Expands AI Platform to Automate Driver Qualification, Compliance and Workforce Records Management, Saving Teams from Time-Consuming Administrative Work February 23, 2026 New AI-powered Workforce Management capabilities eliminate manual document tracking, reduce compliance risk and help prevent costly downtime
Lady Mayor: London must deepen ties with America’s emerging powerhouses February 23, 2026 The US is more than just two coasts. Miami, Dallas and Texas are booking and London is perfectly placed to feel the benefits, says Susan Langley A huge part of the impact of the mayoralty is the 100 days spent overseas, championing the sector and deepening relationships in key markets. When people talk about UK-US [...]